Trial Profile

Baricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study

Status: Not yet recruiting

Phase of Trial: Phase II/III

Latest Information Update: 09 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baricitinib (Primary) ; Lopinavir/ritonavir (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use
Acronyms BARI-COVID

Most Recent Events

19 Apr 2020 Planned number of patients changed from 60 to 200.
19 Apr 2020 Planned End Date changed from 30 Apr 2020 to 30 Jul 2020.
19 Apr 2020 Planned primary completion date changed from 30 Apr 2020 to 30 Jun 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com